Aldeyra Therapeutics to Host Investor Roundtable Q&A
12 Juin 2024 - 1:00PM
Business Wire
Event Scheduled for Thursday, June 20 at
8:00 a.m. ET
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
biotechnology company devoted to discovering and developing
innovative therapies designed to treat immune-mediated and
metabolic diseases, today announced that the company will host an
Investor Roundtable Q&A via webcast on Thursday, June 20, 2024
at 8:00 a.m. ET.
The call will include prepared remarks from Todd C. Brady, M.D.,
Ph.D., President and Chief Executive Officer, followed by a Q&A
session. The call will be open to all current and prospective
Aldeyra shareholders, and participants will be able to submit
questions through the webcast portal during the event. In addition,
beginning Monday, June 17, investors will be able to submit
questions ahead of the call via email to
investorrelations@aldeyra.com.
A live audio webcast and slide presentation will be accessible
from the “Investors & Media” section of the Aldeyra website at
https://ir.aldeyra.com/. A replay will be available for 90 days
following the event.
About Aldeyra Aldeyra Therapeutics is a biotechnology
company devoted to discovering innovative therapies designed to
treat immune-mediated and metabolic diseases. Our approach is to
develop pharmaceuticals that modulate protein systems, instead of
directly inhibiting or activating single protein targets, with the
goal of optimizing multiple pathways at once while minimizing
toxicity. Our product candidates include RASP (reactive aldehyde
species) modulators ADX-629, ADX-246, ADX-248, and chemically
related molecules for the potential treatment of immune-mediated
and metabolic diseases. Our late-stage product candidates are
reproxalap, a RASP modulator for the potential treatment of dry eye
disease and allergic conjunctivitis, and ADX-2191, a novel
formulation of intravitreal methotrexate for the potential
treatment of retinitis pigmentosa.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
Investor & Media: David Burke Tel: (917) 618-2651
investorrelations@aldeyra.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
